The top 100 drugs: a 5-year outlook by therapeutic area, 2026–2031
$546bn of 2025 sales across 12 therapy areas, projected drug by drug with patent expiries, Medicare negotiated prices and new launches. See the method our ready-to-go reports use. Read the report →
Ready-to-go or built around your question
Ready-to-go
The standard report below, on any product in the catalogue. Fixed scope, fixed price, no scoping call.
- Global view plus EU5 and US detail
- Base, low and high scenarios, 2027–2031
- PDF report and Excel model
- Delivered in 5 business days
Portfolio pack
Five ready-to-go analyses ordered together: a therapy area, a competitor set or your own portfolio.
- Same standard scope per product
- One cross-product summary
- Delivered in 10 business days
Custom
Your markets, your question. For pipeline assets not yet approved, single-country deep-dives (Greece, Cyprus, the Balkans, any EU market), launch sequencing, in-licensing and deal screening.
- Scoping call and written proposal
- Your own scenarios and assumptions
- Timeline agreed in the proposal
The ready-to-go 5-year market analysis
- Executive summaryThe 5-year outlook in one page: peak-year range, key drivers and the risks that move it.
- Product and regulatory profileIndications, approvals and status in the EU and US, designations, label changes and exclusivity.
- Patient populationPrevalence, diagnosed and treated patients by market, from published epidemiology.
- Treatment landscapeStandard of care, guidelines and where the product sits in the treatment pathway.
- CompetitionMarketed competitors, late-stage pipeline, biosimilar and generic entry, and loss-of-exclusivity timing.
- Pricing and accessList-price and reimbursement context, HTA outcomes and access barriers by market.
- 5-year revenue scenariosBase, low and high cases for 2027–2031 by region, with uptake, share and price assumptions set out.
- Risks and catalystsUpcoming readouts, regulatory dates, patent events and policy changes that could change the forecast.
Sources: official regulator records (EMA, European Commission, FDA), company filings and reports, published literature and HTA decisions; each fact is referenced. Forecasts are modelled scenarios built on stated assumptions, not guarantees. Not investment advice.
Find your product
Every EU-authorised medicine in the EMA register and every FDA approval in our database. Not listed? Order it anyway: pipeline and unlisted products are covered as custom analyses.
2,527 products match.
| Product | Company | Therapeutic area | Market · date | |
|---|---|---|---|---|
| Toujeo (previously Optisulin) insulin glargine | Sanofi-aventis Deutschland GmbH | Diabetes Mellitus | 🇪🇺 EU 2000-06-26 | Order → |
| Lantus insulin glargine | sanofi-aventis Deutschland GmbH | Diabetes Mellitus | 🇪🇺 EU 2000-06-09 | Order → |
| ViraferonPeg peginterferon alfa-2b | Merck Sharp Dohme Ltd | Hepatitis C, Chronic | 🇪🇺 EU 2000-05-28 | Order → |
| PegIntron peginterferon alfa-2b | Merck Sharp & Dohme B.V. | Hepatitis C, Chronic | 🇪🇺 EU 2000-05-24 | Order → |
| Orgalutran ganirelix | Organon N.V. | Reproductive Techniques, Assisted; Ovulation Induction; Infertility, Female | 🇪🇺 EU 2000-05-16 | Order → |
| Azopt brinzolamide | Novartis Europharm Limited | Glaucoma, Open-Angle; Ocular Hypertension | 🇪🇺 EU 2000-03-09 | Order → |
| IntronA interferon alfa-2b | Merck Sharp & Dohme B.V. | Carcinoid Tumor; Leukemia, Hairy Cell; Lymphoma, Follicular; Hepatitis B, Chronic; Hepatitis C, Chronic; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Melan | 🇪🇺 EU 2000-03-09 | Order → |
| Thyrogen thyrotropin alfa | Sanofi Winthrop Industrie | Thyroid Neoplasms | 🇪🇺 EU 2000-03-09 | Order → |
| Viraferon interferon alfa-2b | Schering-Plough Europe | Hepatitis C, Chronic; Hepatitis B, Chronic | 🇪🇺 EU 2000-03-09 | Order → |
| Zyprexa Velotab olanzapine | CHEPLAPHARM Registration GmbH | Schizophrenia; Bipolar Disorder | 🇪🇺 EU 2000-02-03 | Order → |
| Enbrel etanercept | Pfizer Europe MA EEIG | Spondylitis, Ankylosing; Arthritis, Juvenile Rheumatoid; Arthritis, Psoriatic; Psoriasis; Arthritis, Rheumatoid | 🇪🇺 EU 2000-02-02 | Order → |
| Renagel sevelamer | Sanofi Winthrop Industrie | Renal Dialysis; Hyperphosphatemia | 🇪🇺 EU 2000-01-28 | Order → |
| Tractocile atosiban | Ferring Pharmaceuticals A/S | Obstetric Labor, Premature | 🇪🇺 EU 2000-01-20 | Order → |
| Ammonaps sodium phenylbutyrate | Immedica Pharma AB | Ornithine Carbamoyltransferase Deficiency Disease; Citrullinemia; Carbamoyl-Phosphate Synthase I Deficiency Disease | 🇪🇺 EU 1999-12-07 | Order → |
| Tikosyn dofetilide | Pfizer Limited | Atrial Fibrillation; Atrial Flutter | 🇪🇺 EU 1999-11-29 | Order → |
| NovoRapid insulin aspart | Novo Nordisk A/S | Diabetes Mellitus | 🇪🇺 EU 1999-09-07 | Order → |
| Arava leflunomide | Sanofi-aventis Deutschland GmbH | Arthritis, Rheumatoid; Arthritis, Psoriatic | 🇪🇺 EU 1999-09-02 | Order → |
| Ferriprox deferiprone | Chiesi Farmaceutici S.p.A. | beta-Thalassemia; Iron Overload | 🇪🇺 EU 1999-08-25 | Order → |
| Remicade infliximab | Janssen Cilag International NV | Spondylitis, Ankylosing; Arthritis, Rheumatoid; Psoriasis; Crohn Disease; Arthritis, Psoriatic; Colitis, Ulcerative | 🇪🇺 EU 1999-08-13 | Order → |
| Synagis palivizumab | AstraZeneca AB | Respiratory Syncytial Virus Infections | 🇪🇺 EU 1999-08-13 | Order → |
Order a report or brief us
We confirm scope and send the invoice by e-mail; work starts on confirmation.